We have a multidisciplinary approach to treatment, in other words you benefit from Winship's vast resources in hematology, cardiology, nephrology, neurology and bone marrow transplantation, to provide you with the newest, most effective practices and treatments for plasma cell disorders. Our clinicians develop groundbreaking treatments that produce better outcomes and are adopted by other leading medical programs.
The benefits of having your plasma cell disorder treated here include:
- Access to award-winning physicians who rank among the top hematology experts in the world.
- Coordinated scheduling for appointments among various specialties.
- Access to Winship's Bone Marrow and Stem Cell Transplant Program, the largest and oldest program in Georgia.
- Availability of new treatment options within our clinical trials program.
Our plasma cell dyscrasia program is located at Winship Cancer Institute (Clifton campus).
In our clinic, we treat patients with any one of the following:
- amyloid light-chain (AL) amyloidosis: Proteins produced by cancerous plasma cells take a particular form that allows them to be deposited into various body organs, such as kidney, heart or others, causing damage.
- monoclonal gammopathy of renal significance (MGRS)
- POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, & Skin changes)
Due to the differing types of plasma cell disorders, a variety of tests are used to diagnose specific ones. A complete staging workup may include a physical exam, 24-hour urine test, blood work, imaging tests and bone marrow biopsy.
Other plasma cell disorders such as monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma and high risk myeloma are precancerous conditions and can become multiple myeloma. Visit our multiple myeloma page to learn about treatment options and meet our world-renowned team of specialists.
Your treatment options will be tailored to your diagnosis of your specific type of plasma cell disorder and may vary, but in most cases one or a combination of the following methods will be used:
Targeted drugs and combination therapies: Various drugs are used to treat your condition by directly targeting the abnormal cells in your body. At Winship, we have pioneered the use of these drugs in combination with front-line therapies.
Bone marrow and stem cell transplantation: This treatment consists of destroying diseased bone marrow cells by using higher doses of chemotherapy and in some cases, radiotherapy, and then replacing them with healthy bone marrow or stem cells to help patients regain a new and healthy immune system. Winship has pioneered many advances in bone marrow transplant procedures and drugs. Learn about our Bone Marrow and Stem Cell Transplant Center.
Immunotherapy: A therapy option that uses your own immune system to treat your condition.
In addition to delivering the highest quality medical care, we recognize the importance of the psychological and emotional aspects of dealing with your treatment. Our supportive oncology team addresses these issues in a timely manner with additional support from counselors, nurse navigators, dietitians and social service professionals.
Consider talking with your doctor about participating in a clinical trial at Winship. Through these trials, you may have access to treatments that are not widely available.
For smoldering myeloma and MGUS patients, Sparkcures.com provides information on clinical trials tailored to you. We encourage you to visit their website to learn more.
We understand that this is a very stressful time. We welcome your questions and requests for help. Learn what to expect on your first visit.
Your Treatment Team
- Physician Diagnosticians
- Nurse Navigators
- Adv Practice
- Support Services
- Clinical Trials
- Dr. Hofmeister's practice focuses on plasma cell cancers, including plasmacytomas, multiple myeloma, AL amyloidosis, smoldering myeloma, and monoclonal gammopathies of renal significance.
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
- (404) 778-1900